Then, via LASSO and Cox regression analyses, immune signatures were constructed using HLA-DQA2, HOXA3, and SAA2, and IDH1mt-glioma patients were divided into high-risk and low-risk groups. This evidence concerns the gene HLA-DQA2 and central nervous system cancer.